Cytomegalovirus (CMV) infections manifest across a spectrum of clinical presentations, ranging from asymptomatic to severe life-threatening conditions. Immunocompromised individuals, such as those undergoing chemotherapy or organ transplant recipients, are particularly susceptible to symptomatic CMV infections. Common clinical manifestations include fever, fatigue, and organ-specific symptoms such as pneumonia or gastrointestinal complications. CMV retinitis, a sight-threatening condition, is prevalent in individuals with advanced HIV/AIDS. The management of CMV infections involves antiviral medications like ganciclovir, foscarnet, and cidofovir, which can help inhibit viral replication. Prophylactic use of these drugs is often considered in high-risk populations to prevent the onset of CMV-related complications. Despite advances in treatment, challenges remain, including the potential for drug resistance and the need for continued research to develop more effective therapeutic strategies. Ongoing efforts focus on understanding the immune response to CMV and developing vaccines to prevent primary infections and reactivations in at-risk populations.